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H I G H L I G H T S
• The dual-targeting and reduction-sen-
sitive DOX/ICG@DSHM were devel-
oped for chemo-photothermal combi-
nation therapy.
• The DOX/ICG@DSHM can achieve on-
demand drug release as well as high
uptake efficiency.
• The DOX/ICG@DSHM can realize the
notable tumor ablation under the
guidance of dual-modal optical ima-
ging.
G R A P H I C A L A B S T R A C T






A B S T R A C T
A combination of chemotherapy and photothermal therapy (PTT) against cancer, overcoming the intrinsic limitations
of single-modal chemotherapy or PTT, has emerged as a promising strategy to achieve synergistic therapeutic effect.
However, the lack of precise drug delivery and intelligent drug release based on photo-chemotherapy at specific
tumor sites remained a challenge. Hence, the both tumor-specific targeting molecule (methotrexate) and ligand
(hyaluronic acid)-introduced, glutathione-responsive amphiphiles (deoxycholic acid-hyaluronic acid-methotrexate,
DA-SS-HA-MTX) were developed for synchronous delivery of indocyanine green (ICG) and doxorubicin (DOX). The
as-synthesized DOX/ICG@DSHM remarkably improved the intracellular drug uptake and accumulation owing to
both the CD44/folate receptors-mediated synergistic targeting and the glutathione-triggered rapid drug release.
Moreover, DOX/ICG@DSHM efficiently accumulated at the tumor sites, realizing the notable tumor ablation under
the guidance of dual-modal optical imaging. Taken together, this study provided a promising nanotheranostic agent
for imaging-guided chemo-photothermal combination therapy.
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1. Introduction
In recent years, tremendous concerns have been focused on
searching for more effective combination therapeutic strategies for
cancer [1]. Compared to the conventional chemotherapy, the combined
therapeutic strategies possessing many advantages (e. g., simplicity of
application and minimally invasive local treatment), which can mini-
mize the side effects and enhance the therapeutic efficiency [2,3].
Among all the various combined treatment approaches, the combina-
tion of photothermal therapy and chemotherapy, resulting in superior
synergistic effects, has caused the most attentions to optimize cancer
therapy. Specially, the indocyanine green (ICG, a unique dye approved
by Food and Drug Administration) and doxorubicin hydrochloride
(DOX, a clinical approved chemotherapeutic drug) are usually selected
in the chemo-photothermal therapy (PTT) [4]. Moreover, it also can
utilize the characteristics of the near-infrared (NIR) fluorescence ima-
ging of ICG to realize a real-time monitoring system of cancer ther-
anostics. However, in most of the reported nanosystems [5], the DOX/
ICG were just encapsulated into the non-targeted and non-responsive
nanoparticles, which cannot avoid the premature release in the blood
circulation as well as the insufficient enrichment in the tumor tissues
[6,7]. Apparently, it is highly desirable to exploit stimuli responsive
nanoscale drug delivery systems for targeted delivery of DOX/ICG.
Because of the defective blood-vessel architectures and the im-
mature lymphatic system which could lead to the enhanced perme-
ability and retention (EPR) effect, nanoparticles are prone to passively
accumulate in tumor tissues [8]. However, this passive targeting
strategy lacks active targeting ability, which would lead to limited
treatment efficacy as well as undesirable drug delivery effects. There-
fore, an active targeting strategy, functioning of nanocarrier with re-
ceptor targeting ligand, has been actively pursued [9]. Normally, the
passive targeting strategy or single targeting strategy still faces severe
inherent limitations of their nonspecific uptake by certain kinds of
normal cells, which express low or similar levels of receptors as well. It
was reported that dual or multiple receptors targeting could overcome
this problem by increasing the differentiation between normal and
tumor cells [10]. Apparently, to further improve the accumulation of
therapeutic drug at tumor sites, two separate tumor-specific ligands
could be involved in the same nanoparticles [11]. In this way, dual
receptors targeting strategy can deliver nanoparticles to tumor cells
effectively and specifically [12].
Among a plethora of targeting ligands, hyaluronic acid (HA) and its
Scheme 1. Schematic diagram of the formation process of DOX/ICG@DSHM with their imaging-guided synergistic targeting-promoted photo-chemotherapy.
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derivatives have been extensively investigated in the design of drug
carrier in the pharmaceutical fields. Most of HA-based nanoparticles
have put emphasis on the over expression of HA binding receptors (e.g.,
CD44), which has been found over-expressed on the surface of numerous
tumor cells. Deservedly, HA-based nanoparticles could exhibit an im-
proved cellular uptake through CD44-mediated endocytosis. Besides,
methotrexate (MTX), due to high structural similarity to its analog folic
acid (FA), could also be used as a unique ‘targeting ligand’ with im-
pressive affinity to folate receptors (overexpressed on the surface of a
number of different cancer cells) [13–15]. We hypothesized that higher
efficient synergistic tumor targeting ability could be achieved by con-
jugating the nanoparticles with MTX and HA at the same time.
To achieve an ideal therapeutic effect, dealing with fast release of
the active payloads at the desired site is another challenge to overcome
[16]. Recently, increasing concerns have been focused on the en-
gineering of intracellular stimuli-responsive nanoparticles that are
generally stable under nonspecific biodistribution in vivo (e.g., in blood
circulation) while rapidly release the loaded pharmaceutical agent after
entering the target site (e.g., in tumor cells), resulting in markedly
improved therapeutic efficacy [17,18]. Notably, redox-responsive na-
noparticles, which could be sensitive to differences in the concentra-
tions of glutathione between the intracellular conditions and extra-
cellular environment, are often adopted as the stimulus-responsive
nanoscale drug delivery systems [19–21].
In this work, a smart dual-targeting and reduction-sensitive nano-
system was assembled by deoxycholic acid (DA)-hyaluronic acid (HA)-
methotrexate amphiphilic copolymer. Firstly, the hydrophobic DA was
conjugated with the hydrophilic HA targeting ligand through the disulfide
bond (abbreviated as DA-SS-HA). Then, the synthesized DA-SS-HA
amphiphilic copolymer was further conjugated with targeting metho-
trexate molecules (abbreviated as DA-SS-HA-MTX) for dual active tar-
geting. Subsequently, both the DOX and ICG were physically encapsulated
within DA-SS-HA-MTX self-assembling nanoparticles (abbreviated as
DOX/ICG@DSHM). Meanwhile, both the DOX and ICG were also physi-
cally encapsulated within DA-SS-HA self-assembling nanoparticles (ab-
breviated as DOX/ICG@DSH), which were used as the control. In addition,
the insensitive conjugates (abbreviated as DA-CC-HA-MTX) were also
synthesized using adipic dihydrazide as the linker. Similarly, the in-
sensitive DOX/ICG loaded nanoparticles (abbreviated as DOX/ICG@
DCHM) were also prepared in the same way for comparison.
We hypothesized that once DOX/ICG@DSHM were intravenously ad-
ministrated, the nanoparticles would preferentially accumulate at the
tumor sites via combining of passive targeting of EPR effect-mediated as
well as CD44/folate receptors-mediated active targeting mechanisms. After
internalization by the tumor cells, the disulfide linkage between HA and
DA would induce a rapid drug release of the cargos, achieving an en-
hanced therapeutic effect. In addition, NIR irradiation would induce local
heat generation, which could increase the permeability of cell membranes
to effectively enhance the drug uptake. Especially, by utilizing the DOX/
ICG@DSHM as the theranostic agent, eradication of tumors would be
achieved via the NIR fluorescence imaging-guided chemo-photothermal
combination therapy in one treatment cycle (Scheme 1).
2. Result and discussion
2.1. Synthesis and characterization of DA-SS-HA-MTX
The dual-targeting reduction-responsive polymer DA-SS-HA-MTX
Fig. 1. Characterization of DA-SS-HA-MTX conjugate. (A) Synthetic routes of the DA-SS-HA-MTX. (B) 1H NMR spectra of HA, cystamine, SS-HA, DA, DA-SS-HA, MTX,
and DA-SS-HA-MTX. (C) UV–vis spectra of MTX, DA-SS-HA, and DA-SS-HA-MTX.
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was synthesized via the three distinctive steps (Fig. 1A). Firstly, cy-
stamine-modified HA (HA-SS) were obtained by coupling the carboxyl
group of HA with the amino group of cystamine through carbodiimide-
catalyzed amidation reaction. Secondly, HA-cystamine linkers were
conjugated to the carboxylic group of DA to obtain DA-SS-HA through
amine coupling reaction. Lastly, the γ-carboxylic group of MTX was
attached to the hydroxyl group of DA-SS-HA to synthesize DA-SS-HA-
MTX through an esterification reaction. The chemical structures of DA-
SS-HA-MTX conjugate were further identified by 1H NMR and FT-IR
analysis. As shown in Fig. 1B, characteristic peaks of N-acetyl group and
hydroxyl groups in HA were found at 1.9 and 4.0 ppm in the spectrum
of DA-SS-HA. While the characteristic peaks of methylene groups of
cystamine were also appeared at 2.9 ppm in the spectrum of DA-SS-HA.
Besides, the successful linkage of DA with HA-SS was confirmed by the
characteristic peaks of the methyl group in DA, which appeared at
0.67–1.60 ppm. Furthermore, the successful grafting of MTX on the
polymer backbone of DA-SS-HA was indicated by the characteristic
peaks at 6.8, 7.7, and 8.6 ppm in the spectrum of DA-SS-HA-MTX,
corresponding to the aromatic protons of MTX.
The structure of the DA-SS-HA-MTX was also confirmed by FT-IR
analysis (Fig. S1). As compared to the spectrum of DA and HA-SS, the
new absorption peaks emerged at 1650 (amide I band) and 1564 cm−1
(amide II band) in the spectrum of DA-SS-HA, which were due to the
formulation of amide linkage. In the spectrum of DA-SS-HA-MTX, the
absorption bands at 1600, 1580, and 1450 cm−1 were corresponding to
the substituted benzene of MTX, implying the successful linkage of MTX
with DA-SS-HA. Moreover, the adsorption peak at 1740 cm−1 asso-
ciated with the newly generated ester bond was also appeared in the
spectrum of DA-SS-HA-MTX.
Additionally, the UV–vis spectrum of the DA-SS-HA-MTX was dis-
played in Fig. 1C. It was observed that the physical mixture of DA-SS-
HA and MTX exhibited the superposition of the characteristic peaks of
free MTX and DA-SS-HA. Moreover, compared to the characteristic
absorption peak of free MTX at 300 nm, there was about a 40 nm blue-
shift in the spectrum of DA-SS-HA-MTX at 260 nm. This was possibly
caused by the conjugation between MTX and DA-SS-HA. The above
results of 1H NMR, FT-IR, and UV–vis analysis confirmed the successful
synthesis of DA-SS-HA-MTX, which could be further used as an im-
portant self-assembly motif to construct the dual receptor-targeted
redox-responsive drug delivery systems. In addition, as a control group,
the structure of synthesized insensitive amphiphilic polymer DA-CC-
HA-MTX (Fig. S2) was also identified by 1H NMR analysis (Fig. S3).
2.2. Preparation and characterization of DOX/ICG@DSH and DOX/ICG@
DSHM
Because of the amphiphilicity, DA-SS-HA or DA-SS-HA-MTX con-
jugate could be readily self-assembled into nanoscale structure in
aqueous solution using dialysis method to encapsulate chemother-
apeutic drug (DOX) and photothermal drug (ICG) (designed as DOX/
Fig. 2. TEM image of (A) DOX/ICG@DSHM and (B) DOX/ICG@DSH. SEM image of (C) DOX/ICG@DSHM and (D) DOX/ICG@DSH. (E) Hydrodynamic diameter of
DOX/ICG@DSHM and DOX/ICG@DSH. (F) Size stability of DOX/ICG@DSHM nanoparticles in DI water, PBS, 10% plasma/Heparin in PBS, and FBS within 5 d. (G)
Size changes of DOX/ICG@DSHM after incubation in PBS containing 0 μM, 10 μM, or 10mM of GSH. Inset: Morphological change of DOX/ICG@DSHM detected by
TEM after incubation with GSH for 48 h. (H) Drug release of DOX from DOX/ICG@DSHM after incubation under different conditions. (I) Temperature profiles of PBS,
DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM under the continuous laser irradiation at a power intensity of 1W/cm2. (J) Infrared thermographic images of PBS,
DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM were recorded for 5 min with an infrared thermal imaging camera after continuous laser irradiation.
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ICG@DSH or DOX/ICG@DSHM) [22]. The hydrodynamic particle size,
surface charge, and particle size distribution of the DOX/ICG@DSH and
DOX/ICG@DSHM were measured by dynamic light scattering. The
hydrodynamic particle size of the DOX/ICG@DSH and DOX/ICG@
DSHM were about 149.3 nm and 158.5 nm with low polydispersity
index (≤0.20), indicating a narrow size distribution of these two kinds
of nanosystems (Fig. 2E). The morphology of the DOX/ICG@DSH and
DOX/ICG@DSHM was also observed by transmission electron micro-
scopy (TEM) (Fig. 2A and B) and scanning electron microscope (Fig. 2C
and D), indicating that these two kinds of nanosystems exhibited
spherical shape, excellent monodispersity, and uniform size distribu-
tion. The zeta potential of DOX/ICG@DSHM was about −33.5mV,
which was due to the presence of deprotonated carboxylic groups on
the surface of nanosystems. Moreover, the negatively charged nano-
particles could enhance their circulation half-life, which was ascribed to
their less adsorption to plasma protein [8]. Drug encapsulation effi-
ciency (EE) and drug-loading efficiency (LE) were important for further
clinical application of nanosystems. Herein, the EE of DOX and ICG of
DOX/ICG@DSHM was measured as about 90.5% and 85.9%, respec-
tively. And, the LE of DOX and ICG of DOX/ICG@DSHM was measured
as approximately 7.7% and 7.3%. Meanwhile, the EE of DOX and ICG of
DOX/ICG@DSH was measured as about 89.6% and 83.2%, respectively.
Besides, the LE of DOX and ICG of DOX/ICG@DSH was measured as
approximately 7.6% and 7.1%.
2.3. Stability and photothermal efficiency of DOX/ICG@DSHM
The size stability of DOX/ICG@DSHM were assayed in deionized
(DI) water, phosphate buffered saline (PBS), fetal bovine serum (FBS),
and 10% (v/v) plasma/heparin in PBS respectively (Fig. 2F). The DOX/
ICG@DSHM in DI water and PBS remained similarly to initial size,
implying an excellent long-term stability of nanosystems against ionic
effect. In addition, the stability was also observed by dispersing the
DOX/ICG@DSHM in FBS or plasma/heparin solution. As shown in
Fig. 2F, the initial size of DOX/ICG@DSHM remained unchanged ba-
sically, indicating that the protein binding has few effects on the sta-
bility. These results confirmed that the DOX/ICG@DSHM possessed
excellent size stability in different complex physiological environment.
ICG is an FDA-approved agent to be applied in visual diagnostic and
photothermal therapy. Unfortunately, the further application of ICG is
limited by its numerous drawbacks (i.e. instability in aqueous solution
and prone to self-bleaching) [9]. Thus, the fluorescence stability of
ICG@DSHM was measured by fluorescence analysis (Fig. S4). After
5 days, the fluorescence intensity of ICG@DSHM remained nearly
~90.1%, whereas the fluorescence intensity of free ICG decreased to
~50% of initial intensity. These results indicated that the fluorescence
stability was effectively enhanced by encapsulating ICG into ICG@
DSHM. The protective effect of ICG@DSHM might be ascribed to the
encapsulation of ICG into the nanoparticles, which isolated it from the
aqueous solutions.
In order to observe the photothermal efficiency of DOX/ICG@
DSHM, we investigated the temperature increasing profiles under laser
irradiation (808 nm, 1W/cm2) using an infrared thermal imaging
camera (Fig. 2I and J). Under the laser irradiation (808 nm, 1W/cm2)
for 5min, the temperature of PBS, free ICG, DOX/ICG@DSH, and DOX/
ICG@DSHM increased to 29.1, 42.3, 53.9, and 54.3 °C respectively.
DOX/ICG@DSH and DOX/ICG@DSHM displayed a higher temperature
increase than that of free ICG under laser irradiation, which may be due
to the enhancement of ICG stability by encapsulating it into the nano-
particles.
2.4. Redox-induced destabilization of DOX/ICG@DSHM
In order to investigate the reduction responsiveness, the DOX/ICG@
DSHM were incubated with different concentrations of GSH solutions,
which mimicked the distinctive environments in vivo. The respective
variations of morphologies and hydrodynamic particle sizes of the
DOX/ICG@DSHM were monitored. As shown in Fig. 2G, the hydro-
dynamic particle size of the DOX/ICG@DSHM increased to 529.7 nm
after being exposure to 10mM of GSH (corresponding to the levels in
tumor cells) for 48 h, accompanying with broadening of size distribu-
tion. This might be attributed to the cleavage of the disulfide linkages
between the HA polymer and DA molecules, which lead to the dis-
assembly of the nanoparticles followed by the formation of aggrega-
tion/precipitation. These results were also confirmed by the typical
TEM images of DOX/ICG@DSHM after incubation with 10mM of GSH
for 48 h (Fig. 2G). In contrast, when immersed the DOX/ICG@DSHM
into 0mM or 10 μM of GSH (mimicking the plasma levels), no obvious
variation in morphology and hydrodynamic particle size was observed
after 48 h, indicating that the DOX/ICG@DSHM could keep stable in
the blood circulation.
2.5. In vitro reduction-responsive release
Drug delivery systems, which could be capable of fast releasing
pharmaceutical agent at desired site, are tending to induce enhanced
therapeutic effect [23]. In order to assess the reduction-responsive re-
lease behavior of DOX/ICG@DSHM, the in vitro cumulative release of
DOX was conducted in presence of different GSH/pH levels. The cu-
mulative DOX release profiles were displayed in Fig. 2H. Firstly, both
the DOX/ICG@DSHM and DOX/ICG@DCHM displayed pH-dependent
drug release behavior with greater rate of drug release at lower pH
value. Besides, in the absence of GSH (pH=7.4), the DOX/ICG@DSHM
exhibited an initial fast drug release with ~15% of DOX released within
12 h. However, little drug release was observed during the following
18 h and approximately ~28% of cumulative drug release was obtained
at 48 h. This insufficient DOX release could be ascribed to the en-
capsulation of DOX within the hydrophobic core of nanoparticles. In
addition, in the presence of 10 μM of GSH (mimicking the plasmatic
levels), the release profile displayed the similar pattern, in which ~18%
of DOX was released at initial 12 h, followed by slow release in the
subsequent 36 h. In contrast, in the presence of 10mM of GSH (mi-
micking tumor cells environment), the drug release rate was dramati-
cally accelerated, in which ~38% of DOX was released within 12 h and
almost attained over ~85% at 48 h. This accelerated release of DOX
from DOX/ICG@DSHM might be attributed to the rapid cleavage of
disulfide bonds, which would result in the disassembly of nanosystems
associated with the destruction of structural integrity of the nano-
particles, and thus promote the diffusion of drug from the hydrophobic
core of nanoparticles. In addition, only ~21% of DOX released from
DOX/ICG@DCHM in the presence of 10mM of GSH at 48 h (Fig. S5).
The results above indicated that the DOX/ICG@DSHM would be
stable in the plasma after intravenous administration without releasing
a substantial amount of DOX, whereas could trigger the drug release
inside tumor cells with a rapid pattern. Therefore, the DOX/ICG@
DSHM are expected to be a kind of highly promising drug delivery
system to control the release of anticancer drug smartly for improve-
ment of therapeutic efficacy.
2.6. Cellular uptake study
The cellular uptake study of the DOX/ICG@DSHMwas visualized by
the confocal laser scanning microscopy (CLSM). MCF-7 cells, highly
expressed folate and CD44 receptor on the surface of cell membrane,
were incubated with DOX/ICG@DSHM for 1 and 4 h. The cellular up-
take of DOX/ICG and DOX/ICG@DSH was performed for comparison.
As shown in Fig. 3, the fluorescence signal of DOX was primarily existed
in the nuclei of MCF-7 cells in the free DOX solution-treated group,
which was attributed to the fact that small DOX molecules entered
MCF-7 cells through passive diffusion. Conversely, the fluorescence
signal of DOX in MCF-7cells treated with DOX/ICG@DSHM seemed to
be existed in the cytoplasm as well as nuclei, indicating DOX/ICG@
F. Yu, et al. Chemical Engineering Journal 380 (2020) 122426
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DSHM were taken up into MCF-7 cells by endocytosis. Besides, the
fluorescence signal of ICG was homogenously distributed in the cyto-
plasm in MCF-7 cells in the free ICG solution-treated group, which was
attributed to the binding interaction of ICG with intracellular protein
(glutathione S-transferase) [24]. Specially, the free doxorubicin hy-
drochloride was taken up rapidly by MCF-7 cells, principally owing to
the fast passive diffusion of small molecule across cellular membranes
[25,26]. On the contrary, due to altered uptake pathway, the fluores-
cence intensity of DOX and ICG in MCF-7 cells treated with DOX/ICG@
DSHM gradually increased with the incubation of time, indicating
classical time-dependent cellular uptake behavior.
In addition, the stronger fluorescence signal of both DOX and ICG
was observed in the DOX/ICG@DSHM-treated groups. This finding in-
dicated that the simultaneous decoration of both MTX and HA on the
surface of the nanoparticles would enhance the cellular uptake.
Especially, it should be worth noting that the green fluorescence signal
of DOX could be detected in the cell nuclei of MCF-7 cells after 4 h
incubation with the DOX/ICG@DSHM, indicating the efficient cellular
uptake of DOX/ICG@DSHM and subsequent desired intracellular re-
lease of DOX.
To investigate the dual receptor-targeting mechanism of DOX/ICG@
DSHM, the competitive experiments by pre-treating with excess free
FA/HA were conducted. As shown in Fig. 4A, the fluorescence signal of
the DOX/ICG@DSHM groups was apparently weakened when the free
HA or free FA were pre-incubated in the cell culture medium. This was
due to the significant decrease of availability of both folate and CD44
receptors on the surface of MCF-7 cells. This result demonstrated that
DOX/ICG@DSHM could specifically interact with folate and CD44 dual
receptors. This targeted drug delivery strategy would lead to enhanced
therapeutic efficiency as well as reduction of side effects.
The cellular uptake efficiency of DOX/ICG@DSHM-treated cancer
cells with or without pre-incubation of folate and HA was also quan-
titatively determined by flow cytometry. As shown in Fig. 4B, the values
of the fluorescence intensity of DOX/ICG@DSHM increased as com-
pared to that of the DOX/ICG@DSH, which was attributed to the sy-
nergistic enhancement of drug uptake efficiency via dual receptor-
mediated endocytosis. Meanwhile, pre-treating with excess amount of
FA or HA in the DOX/ICG@DSHM-treated MCF-7 cells could sig-
nificantly reduce the fluorescence intensity in comparison to the DOX/
ICG@DSHM group without pre-treatment. Thus, both qualitative and
quantitative results confirmed that the DOX/ICG@DSHM could bind to
both folate and CD44 receptors specifically and selectively, resulting in
the synergistic targeting effect.
To further test the dual receptor-targeting mechanism of DOX/
ICG@DSHM, we measured the targeting specificity of DOX/ICG@
DSHM using MCF-7 cells with high-level folate/CD44 receptor expres-
sion, A549 cells with high-level CD44 receptor expression and the
normal LO2 cells with low-level folate/CD44 receptor expression.
Flow cytometry was used to quantify the cellular uptake of DOX/
ICG@DSHM by these three kinds of cells (Fig. S7). The fluorescence
intensity from DOX/ICG@DSHM in MCF-7 cells was stronger than that
of A549 cells, indicating that fewer DOX/ICG@DSHM were uptaken by
A549 cells. This was ascribed to low-level expression of folate receptor
on the surface of the A549 cells. Meanwhile, the LO2 cells displayed the
weakest fluorescence intensity, indicating that fewest DOX/ICG@
DSHM were taken into normal cells. This was attributed to extremely
low-level expression of both folate and CD44 receptors on the surface of
the LO2 cells.
Specially, the fluorescence intensity from DOX/ICG@DSHM in
MCF-7 cells was approximately 2.1 and 3.8-fold higher than that in
Fig. 3. Confocal laser scanning microscopy images of MCF-7 cells incubated with DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM for 1 and 4 h. Scale
bars= 20 μm. Blue signal, DAPI; green signal, DOX; red signal, ICG.
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Fig. 4. (A) Confocal laser scanning microscopy of MCF-7 cells incubated with DOX/ICG@DSH and DOX/ICG@DSHM in the absence or presence of free FA/HA after
4 h. Scale bars= 20 μm. (B) Mean fluorescence intensity of MCF-7 cells treated with DOX/ICG@DSH and DOX/ICG@DSHM in the absence or presence of free FA/HA
after 4 h.
Fig. 5. (A) Cell viability of MCF-7 cells treated with MTX, DSHM, DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM with or without 808-nm laser irradiation (1W/
cm2, 5min). (B) Cell viability of Hela cells treated with DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM with or without 808-nm laser irradiation (1W/cm2,
5 min). (C) Calcein-AM/PI co-stained fluorescence images of MCF-7 cells treated with PBS, DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM with 808-nm laser
irradiation. Living cells were stained green with calcein-AM, and dead cells were stained red with PI. Scale bars= 100 μm.
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A549 cells and LO2 cells, respectively. Apparently, DOX/ICG@DSHM
NPs possessed highly specific selectivity for folate/CD44 receptors-
overexpressed MCF-7 cells.
2.7. Cytotoxicity test
To investigate the chemo-photothermal therapy of the DOX/ICG@
DSHM in vitro, the viability of MCF-7 cells and HeLa cells bearing
single- or dual-modality therapy was assessed by MTT assay. As shown
in Fig. 5A and B, in the absence of near-infrared (NIR) laser irradiation,
the free DOX, DOX/ICG@DSH, and DOX/ICG@DSHM-treated MCF-7
and HeLa cells displayed an inhibitive effect on the cell proliferation in
a dose-dependent manner. Besides, compared with the DOX/ICG@DSH
(IC50, 5.4 μg/mL), the DOX/ICG@DSHM (IC50, 3.5 μg/mL) exhibited a
significant increase of cytotoxic activity to MCF-7 cells and HeLa cells.
This mainly might be the result of the high-efficiency affinity of DOX/
ICG@DSHM to these two kinds of cancer cells, which enhanced the
uptake of DOX/ICG@DSHM through dual receptor-mediated en-
docytosis, causing an excellent inhibition of cell proliferation. Besides,
this remarkably enhanced cytotoxic activity to MCF-7 cells and HeLa
cells could be partly ascribed to the cytotoxicity of MTX.
In the presence of NIR laser irradiation, it was noted that the cell
viability of DOX/ICG@DSH (IC50, 1.2 μg/mL) and DOX/ICG@DSHM
(IC50, 0.6 μg/mL) groups were much lower than those without irra-
diation (Fig. 5A). The enhanced cytotoxicity might be attributed to the
fact that ICG could induce hyperthermia, which leads to severe pho-
tothermal damage on tumor cells. Moreover, the hyperthermia would
also trigger the rapid release of DOX from the nanoparticles, which
increased the intracellular concentration of DOX and accelerated a
faster diffusion of DOX into the nucleus. Lastly, the growth inhibition
effect on the cells was promoted.
Subsequently, we further investigated the synergistic cytotoxicity of
DOX/ICG@DSHM against MCF-7 cells with chemotherapy from DOX
and photothermal injury from ICG. Fig. S8 showed that DOX/ICG@
DSHM had the IC50 value of 0.6 μg/mL under irradiation, and exhibited
significant cytotoxicity advantage over free DOX (IC50, 2.6 μg/mL) and
ICG@DSHM under irradiation (IC50, 2.5 μg/mL). Specially, the combi-
nation index (CI), providing quantitative information of the combina-
tion effect, was also calculated. CI values lower than, equal to, or higher
than 1 denote synergism, additivity, or antagonism, respectively. Here,
the combination index (CI) was calculated to be 0.5, which indicated
the synergistic effect of DOX/ICG@DSHM in photothermal therapy and
chemotherapy (CI < 1 represented synergism) [27,28]. Apparently,
compared with the monotherapy of photothermal therapy or che-
motherapy, the photo-chemotherapy of DOX/ICG@DSHM under irra-
diation displayed remarkably synergistic therapeutic efficiency.
To visually investigate the in vitro therapeutic effect of DOX/ICG,
DOX/ICG@DSH, and DOX/ICG@DSHM, MCF-7 cells were stained by
calcein-AM and propidium iodide (PI) to distinguish the live and dead
cells, respectively. As shown in Fig. 5C, all the MCF-7 cells exhibited
green fluorescence in the PBS group, suggesting that the pure laser ir-
radiation is relatively safe. Specially, once laser irradiation was added
on the DOX/ICG@DSHM-treated group, great amounts of MCF-7 cells
were killed, which was likely caused by hyperthermic cytotoxicity of
ICG and chemotherapeutic cytotoxicity of DOX. In addition, hy-
perthermia could induce the enhancement of membrane permeability,
partly augmenting the internalization of DOX. The results suggested
that the simultaneous synergistic cytotoxic effect of DOX/ICG@DSHM
on MCF-7 cells could be achieved under the laser irradiation. Besides,
the above result was in accordance with the MTT assay. Moreover, in
Fig. 6. (A) In vivo NIR fluorescence imaging of MCF-7 tumor-bearing nude mice at 1, 2, 6, 12, and 24 h post-i.v. injection of DOX/ICG, DOX/ICG@DSH, and DOX/
ICG@DSHM. (B) In vivo PA imaging of MCF-7 tumor-bearing nude mice at 6 h post-i.v. injection of DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM. (C) Ex vivo
NIR fluorescence imaging and (D) average NIR fluorescence intensity of tumors/major organs of MCF-7 tumor-bearing nude mice at 6 h post-i.v. injection of DOX/
ICG, DOX/ICG@DSH, and DOX/ICG@DSHM.
F. Yu, et al. Chemical Engineering Journal 380 (2020) 122426
8
vitro cytotoxicity of the DOX/ICG@DSHM-treated group was also much
more effective in comparison with that of DOX/ICG@DCHM-treated
group (Fig. S6). Furthermore, combined with the result of in vitro drug
release and cytotoxicity, the reduction-responsive DOX/ICG@DSHM
with excellent performances were investigated in the following studies.
2.8. In vivo fluorescence/PA imaging
The biodistribution of the DOX/ICG@DSHM were employed to de-
termine the tumor-targeting capability using noninvasive NIR imaging
technique. Different formulations including DOX/ICG, DOX/ICG@DSH,
and DOX/ICG@DSHM were administrated into the MCF-7 tumor-
bearing nude mice by intravenous injection respectively. Fluorescence
signals of the DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM-
treated mice were distributed in the whole body at1 h after intravenous
injection (Fig. 6A). Then, strong fluorescence signals of the dual-tar-
geting DOX/ICG@DSHM could be observed in the tumor at 6 h after
intravenous injection. Moreover, the fluorescence signals from tumor
are gradually increased and these fluorescence signals could be de-
tected even at 24 h. In contrast, weaker fluorescence/PA signals of the
free DOX/ICG and single-targeting DOX/ICG@DSH-treated group were
detected at the tumor sites (Fig. 6A and B). The results revealed the
important role of HA and MTX in promoting the efficient tumor accu-
mulation of DOX/ICG@DSHM at the tumor sites via dual-active tar-
geting mechanisms. Besides, the result also implied the prolonged blood
circulation of DOX/ICG@DSH and DOX/ICG@DSHM.
In addition, after 24 h post-injection, the mice were immediately
euthanized, and then the tumors and normal organs were excised for ex
Fig. 7. (A) Time-dependent tumor temperature increase and (B) infrared thermal images of MCF-7 tumor-bearing nude mice irradiated by 808-nm laser (1W/cm2) at
6 h after intravenous injection of PBS, free DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM. (C) Relative tumor volume and (D) body weight changes of MCF-7
tumor-bearing nude mice during the treatment. (E) Representative photographs of the excised tumors at the end of the treatment. (F) H&E staining of the excised
tumors.
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vivo fluorescence imaging (Fig. 6C and D). Superior fluorescence signals
were also observed in the tumors of the DOX/ICG@DSHM-treated
group compared to those of DOX/ICG@DSH and free DOX/ICG-treated
group, confirming the efficient accumulation of dual-active targeting
nanosystems at the tumor sites. Besides, it was undeniable that the
relatively strong fluorescence of both DOX/ICG@DSHM and DOX/
ICG@DSH-treated groups could be also observed in the liver, resulting
from the non-specific uptake by reticulo-eneothelial system (RES).
Notably, the average fluorescence intensity of DOX/ICG@DSHM in the
tumors was 2.5-fold than that of DOX/ICG@DSH. Overall, these results
decisively validated excellent specific tumor dual-targeting of DOX/
ICG@DSHM, which could be attributed to the advantages of EPR effect-
mediated passive targeting combined with active targeting cellular
uptake.
2.9. In vivo photothermal effect and chemo-photothermal efficiency
Encouraged by the above in vitro and in vivo results, the investiga-
tion of synergistic chemo-photothermal therapy mediated by DOX/
ICG@DSH and DOX/ICG@DSHM were further conducted on BALB/C
nude mice. The mice were injected intravenously with PBS, DOX/ICG,
DOX/ICG@DSH, and DOX/ICG@DSHM respectively.
Firstly, the photothermal imaging was recorded using infrared
imaging camera after 5min laser irradiation (808 nm, 1W/cm2, 5min).
After 808 nm irradiation for 5min, the temperatures in the PBS-treated
negative control groups and free DOX/ICG-treated positive control
groups displayed negligible temperature changes, which was ineffective
to damage tumor tissues (temperature above 42–47 °C was reported to
induce the selective destruction of the tumor cells) [29]. In contrast, the
tumor surface temperature could rapidly rise to 47.7 °C and 52.6 °C
after injecting with DOX/ICG@DSH and DOX/ICG@DSHM, respec-
tively, which could create irreversible tumor tissue damage (Fig. 7A and
B). More importantly, the DOX/ICG@DSHM induced a higher tem-
perature in the tumor areas than that of DOX/ICG@DSH, implying the
superiority of folate/CD44 receptor-mediated cellular uptake and in-
ternalization with the help of EPR effect-mediated passive tumor tar-
geting.
To monitor the tumor growth, the tumor volumes were also re-
corded (Fig. 7C). Rapid growth occurred in PBS or PBS plus laser
groups, indicating that the 808 nm laser irradiation alone had a negli-
gent effect on the tumor growth. Additionally, the tumor volume of the
free DOX/ICG-treated group also grew rapidly after exposing to the
laser or not, which indicated that the tumor growth could not be in-
hibited effectively by single injection of DOX/ICG at low dose. These
Fig. 8. H&E staining of primary organs of MCF-7 tumor-bearing mice treated with DOX/ICG, DOX/ICG@DSH, and DOX/ICG@DSHM with or without 808-nm NIR
irradiation. Scale bars= 300 μm.
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were resulted from the insufficient concentration enrichment of DOX
and ICG in tumors, which was a universal biomedical phenomenon
caused by poor pharmacokinetics of small molecular drug. Besides, in
the DOX/ICG@DSHM and DOX/ICG@DSH-treated groups without NIR
laser irradiation, the tumor growth was slightly inhibited, which was
attributed to the higher accumulation of DOX/ICG@DSHM and DOX/
ICG@DSH in tumors than that of free DOX/ICG. Notably, by treating
with DOX/ICG@DSHM and DOX/ICG@DSH under NIR lase irradiation,
the tumor growth on mice was greatly inhibited due to the combination
of the chemo-photothermal treatment. More importantly, the tumor of
mice treated with DOX/ICG@DSHM plus laser irradiation was com-
pletely ablated without tumor recurrence (Fig. 7E). This result not only
indicated that the excellent synergistic therapy was very important but
also confirmed that the dual targeted delivery strategy of DOX/ICG@
DSHM could enhance the intracellular accumulation of DOX/ICG, re-
sulting in a more pronounced chemotherapeutic and photothermal
cytotoxicity. Additionally, the reduction-responsive drug delivery
system also avoided the unwanted leakage of DOX/ICG in the blood
circulation, which could guarantee the effective enrichment of both
chemotherapeutic drug and photothermal agent in tumor. Moreover,
the antitumor effect was also investigated using H&E staining. As
shown in Fig. 7F, the DOX/ICG@DSHM-treated group plus laser irra-
diation displayed the superior cell-killing effect with widespread
apoptosis and necrosis of cancer cells.
Furthermore, the body weights of the mice in each group, an in-
dicator of the treatment-induced toxicity [30], were also monitored. As
shown in Fig. 7D, there was no significant variation in the DOX/ICG@
DSHM-treated group plus laser irradiation, implying that there was no
acute side effect in this combination therapy. In addition, the histology
analysis of H&E-stained major organs of the DOX/ICG@DSHM-treated
group plus laser irradiation proved no obvious sign of organ damage or
other abnormality (Fig. 8).
3. Conclusion
In summary, we synthesized a novel dual-targeting reduction-re-
sponsive DOX/ICG@DSHM by the co-encapsulation of DOX/ICG using
DA-SS-HA-MTX, which combined both synergistic active targeting
ability and chemo-photothermal therapy for cancer treatment. DOX/
ICG@DSHM possessed on-demand release ability of DOX and re-
markably enhanced the photo-stability of ICG. The dual-targeting DOX/
ICG@DSHM could effectively promote the cellular uptake of DOX/ICG
via folate/CD44 receptor-mediated endocytosis. In addition, the DOX/
ICG@DSHM could realize an efficient tumor accumulation with pro-
longed blood circulation, which was confirmed by in vivo NIR fluores-
cence and PA imaging. Notably, under laser irradiation, this multi-
modal therapy not only greatly induced cancer cell death in vitro, but
also significantly suppressed tumor growth in vivo. Hence, the dual-
targeting reduction-responsive DOX/ICG@DSHM with NIR laser irra-
diation would be a promising strategy for enhancing chemo-photo-
thermal anticancer therapy.
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